TNYA Insider Trading

Insider Ownership Percentage: 32.76%
Insider Buying (Last 12 Months): $24,999,998.80
Insider Selling (Last 12 Months): $71,850.01

Tenaya Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Tenaya Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$25Mbought$11ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M-$10M$0$10M$20MTotal Insider BuyingTotal Insider Selling

Tenaya Therapeutics Share Price & Price History

Current Price: $0.70
Price Change: Price Increase of +0.0287 (4.28%)
As of 03/14/2025 05:00 PM ET

This chart shows the closing price history over time for TNYA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AprMayJunJulAugSepOctNovDecJanFebMar$0.70Closing price on 03/15/25:

SEC Filings (Institutional Ownership Changes) for Tenaya Therapeutics (NASDAQ:TNYA)

90.54% of Tenaya Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TNYA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$4.25Mbought$2.46MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4M-$2M$0$2M$4MTotal InflowsTotal Outflows
Tenaya Therapeutics logo
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Read More on Tenaya Therapeutics

Today's Range

Now: $0.70
Low: $0.66
High: $0.74

50 Day Range

MA: $1.06
Low: $0.44
High: $1.52

52 Week Range

Now: $0.70
Low: $0.39
High: $5.39

Volume

5,573,205 shs

Average Volume

2,061,057 shs

Market Capitalization

$61.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.83

Who are the company insiders with the largest holdings of Tenaya Therapeutics?

Tenaya Therapeutics' top insider shareholders include:
  1. Group Gp Lp Column III (Major Shareholder)
  2. Faraz Ali (CEO)
  3. Timothy Hoey (Insider)
  4. Whittemore Tingley (Insider)
  5. Tomohiro Higa (SVP)
  6. Chihiro Saito (SVP)
Learn More about top insider investors at Tenaya Therapeutics.

Who are the major institutional investors of Tenaya Therapeutics?

Tenaya Therapeutics' top institutional investors include:
  1. JPMorgan Chase & Co. — 6.51%
  2. Geode Capital Management LLC — 1.60%
  3. abrdn plc — 0.76%
  4. Northern Trust Corp — 0.60%
  5. Nuveen Asset Management LLC — 0.44%
  6. Trustees of Columbia University in the City of New York — 0.37%
Learn More about top institutional investors of Tenaya Therapeutics stock.

Which major investors are selling Tenaya Therapeutics stock?

Within the previous quarter, TNYA stock was sold by these institutional investors:
  1. Price T Rowe Associates Inc. MD
  2. Barclays PLC
  3. Squarepoint Ops LLC
  4. Millennium Management LLC
  5. XTX Topco Ltd
  6. Geode Capital Management LLC
  7. Dimensional Fund Advisors LP
  8. Bank of America Corp DE
Within the last year, company insiders that have sold Tenaya Therapeutics company stock include:
  1. Group Gp Lp Column III (Major Shareholder)
  2. Faraz Ali (CEO)
  3. Timothy Hoey (Insider)
  4. Whittemore Tingley (Insider)
Learn More investors selling Tenaya Therapeutics stock.

Which major investors are buying Tenaya Therapeutics stock?

During the last quarter, TNYA stock was purchased by institutional investors including:
  1. JPMorgan Chase & Co.
  2. Trustees of Columbia University in the City of New York
  3. Virtu Financial LLC
  4. Deutsche Bank AG
  5. Sei Investments Co.
  6. Nuveen Asset Management LLC
  7. abrdn plc
  8. Commonwealth Equity Services LLC